INT67332

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 1996
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 8
Total Number 8
Disease Relevance 7.95
Pain Relevance 2.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (ITGA4) plasma membrane (ITGA4)
Anatomy Link Frequency
leukocyte 2
blood 1
ITGA4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Nav1.7 6 100.00 Very High Very High Very High
nav1.8 3 100.00 Very High Very High Very High
Inflammation 68 97.40 Very High Very High Very High
cINOD 3 95.56 Very High Very High Very High
Pain 5 92.48 High High
antagonist 3 91.36 High High
Spinal cord 2 91.16 High High
hyperexcitability 2 87.52 High High
sodium channel 3 82.24 Quite High
Congenital analgesia 1 81.04 Quite High
Disease Link Frequency Relevance Heat
Adhesions 187 100.00 Very High Very High Very High
Wound Healing 3 99.56 Very High Very High Very High
Chronic Obstructive Pulmonary Disease 44 99.20 Very High Very High Very High
Frailty 8 98.60 Very High Very High Very High
Asthma 20 98.44 Very High Very High Very High
Nicotine Addiction 366 97.72 Very High Very High Very High
INFLAMMATION 83 97.40 Very High Very High Very High
Disease 59 96.88 Very High Very High Very High
Decubitus Ulcers 1 96.24 Very High Very High Very High
Pain 5 92.48 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Here, we review our efforts to use rational design to identify potent, selective inhibitors of VLA-4.
Negative_regulation (inhibitors) of VLA-4
1) Confidence 0.51 Published 2004 Journal Curr Top Med Chem Section Abstract Doc Link 15544540 Disease Relevance 0.68 Pain Relevance 0.21
Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma.
Negative_regulation (inhibitors) of VLA-4 associated with asthma
2) Confidence 0.38 Published 2004 Journal Curr Top Med Chem Section Title Doc Link 15544540 Disease Relevance 0.73 Pain Relevance 0.20
Two series have been developed, one that has high selectivity for the activated over the non-activated state of the receptor, and the other which is non-selective inhibiting both activated and non-activated VLA-4.
Negative_regulation (inhibiting) of VLA-4
3) Confidence 0.38 Published 2004 Journal Curr Top Med Chem Section Abstract Doc Link 15544540 Disease Relevance 0.58 Pain Relevance 0.17
However, a recent comparison of adhesion molecule expression profiles on leukocyte (L-selectin, VLA-4, and the three ?
Negative_regulation (comparison) of VLA-4 in leukocyte associated with adhesions
4) Confidence 0.19 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2669563 Disease Relevance 2.19 Pain Relevance 0
However, a recent comparison of adhesion molecule expression profiles on leukocyte (L-selectin, VLA-4, and the three ?
Negative_regulation (comparison) of VLA-4 in leukocyte associated with adhesions
5) Confidence 0.19 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2671531 Disease Relevance 2.19 Pain Relevance 0
We found decreased LFA-1 and VLA-4 on peripheral blood leukocytes in SCI patients and lower levels of CAMs in SCI patients with pressure ulcers than in those without them.
Negative_regulation (decreased) of VLA-4 in blood associated with decubitus ulcers and frailty
6) Confidence 0.13 Published 1996 Journal Immunol. Res. Section Abstract Doc Link 8988397 Disease Relevance 0.90 Pain Relevance 0.08
Ranolazine also blocks wild-type Nav1.7 and Nav1.8 channels in a use-dependent manner.
Negative_regulation (blocks) of wild-type associated with nav1.8 and nav1.7
7) Confidence 0.07 Published 2010 Journal Mol Pain Section Abstract Doc Link 20529343 Disease Relevance 0.56 Pain Relevance 1.47
caused a dose-dependent decrease in wild-type PPAR?
Negative_regulation (decrease) of wild-type
8) Confidence 0.01 Published 2006 Journal BMC Med Genet Section Body Doc Link PMC1368963 Disease Relevance 0.12 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox